7Groom AC. The microcirculatory Society Eugene M. Landis award lecture. Microcirculation of the spleen: new concepts, new challenges. Microvasc Res, 1987,34(3): 269-289.
8Crapnell K,Zanjani ED, Chaudhuri A, et al. In vitro infection of megakaryocytes and their precursors by human cytomegalovirus. Blood,2000,95(2) :487-493.
3[2]Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus (SLE).Arthritis Rheum, 1982, 25(2): 1271.
4[3]Richert KE. Hematologic complication of rheumatic disease.Hematology/Oncology. 1987,1(4):301-320.
5[4]Arnal C, Piette JC, Leone J, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus:59 cases. J Rheumatol, 2002, 29: 75-83.
6[5]Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum, 1992,35:630-640.
7[6]Borg E J, Kallenberg CG. Treatment of severe thrombocytopenia in systemic lupus erythematosus with intravenous gammaglobulin.Ann Rheum Dis, 1992, 51: 1149-1151.
8[7]Mok CC, Lee KW, Ho CT, et al. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a Southern Chinese population. Rheumatology (Oxfoud), 2000, 39:399.
9[8]Edwaud B, Ronald H. Human megakaryocyte progenitor cells.Semin Hematol, 1998, 35: 183-191.
10[9]Richards EM, Baglin TP. Quantitation of reticulated platelets:methodology and clinical application. Br J Haematol, 1995, 91:445-451.
